|
Thursday November 2, 2000 COMPANY PRESS RELEASE Transgenomic CEO Collin D'Silva Interviewed by Major Investor Site Interview on wallstreetreporter.com SAN JOSE, Calif., and OMAHA, Neb., (November 2, 2000) - In an exclusive interview with Wallstreetreporter.com, Transgenomic CEO Collin D'Silva spoke about the company, its partners, potential market opportunities and future. Wallstreetreporter.com posted the interview on their website today (http://www.wallstreetreporter.com). The interview with Senior Analyst Tara Reza came just one day after Transgenomic announced its third-quarter revenues, which exceeded expectations. D'Silva is confident about Transgenomic's position in the global market. "We have the technology that's currently validated, that's the technology of choice in understanding genetic variation," D'Silva said during the interview. "The key tool for the next stage of genomics is understanding genetic variation." The audio interview is posted under "Today's CEO Interviews" and can be accessed at http://www.wallstreetreporter.com or www.transgenomic.com. About Transgenomic Transgenomic provides innovative research tools to the genomics segment of the life sciences industry. These tools enable researchers to discover and understand variation in the human genetic code, or genome, in order to accelerate and improve drug development and diagnostics. The company believes its WAVE® System will become a leading tool to analyze genetic mutations. The WAVE® System allows researchers to analyze both known and unknown genetic mutations faster, with more accuracy and at a lower cost than other commercially available techniques. As efforts to sequence the human genome near completion, understanding variations in the genetic sequence, or mutation analysis, is becoming the vital link to the development of new diagnostic and therapeutic products. By comparing genetic mutations in the genome to the occurrence of diseases or particular traits, correlation can be made between genes and specific diseases or traits. The WAVE® System, unlike tools employing more conventional technologies, can detect these genetic mutations without previous knowledge of their existence or position. As a result, the WAVE® System provides researchers a more accurate and efficient means of performing the experiments necessary to identify mutations and to correlate the relationships between mutations and diseases. Forward-Looking Statement This press release may contain forward-looking statements that reflect management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results. Such statements are subject to certain factors, risks and uncertainties described from time to time in Transgenomic, Inc.'s reports to the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. For more information, contact:
|